WEBINARS

In these uncertain times, we’re offering our community a way to stay connected and share ideas. Every week, we’re creating a virtual space to come together and explore the most important topics in the industry right now.

Every webinar is free to attend via GoToWebinar. 

UPCOMING WEBINARS

Building nimble gene therapy start-ups 

Thursday 28 May - 4pm BST/11am EST

Hear from Eric Michael David, CEO, BridgeBio Gene Therapy as we discuss:

  • Hiring versus outsourcing
  • Working with academic labs
  • Nimble CMC approaches

Eric Michael David, CEO, BridgeBio Gene Therapy

REGISTER HERE

 

Eric Michael David, CEO, BridgeBio Gene Therapy

Building an Agile Operational Platform for Allogeneic Cell Therapies - From chronic indications to acute and up to global disease

Thursday 4 June - 2pm BST/9am EST

Hear from Lior Ravivi, Vice President Development & Operations, Pluristem as we discuss:

  • Discuss the unique challenges of global ATMP supply chains and the challenges of building a lean and efficient global supply network for these products
  • Discuss building a flexible operational framework for allogeneic delivery in Israel and beyond
  • Examine ways in which Pluristem were able to adjust their logistical framework and supply networks to increase speed of response and decrease time to patient

Lior Ravivi, Vice President Development & Operations, Pluristem

REGISTER HERE

 

Lior Ravivi, Vice President Development & Operations, Pluristem

Development, transfer and validation of analytical methods for Cell and Gene Therapy products: Learnings & challenges  

Thursday 9 July - 4pm BST/11am EST

Hear from Molmed as we discuss:

  • How define analytical panel and analytical strategy for testing and characterization of LV vector and genetically modified cells
  • Design of an LV Infectious titre with high throughputs automatic station
  • Optimization of Replication Competent Lentivirus detection Design of a qPCR to detect Residual plasmids DNA

Francesca Rossetti, Analytical Methods Development Manager, MolMed

Giuliana Vallanti, Development and Quality Control Director, MolMed

REGISTER HERE

 

Sponsored by: Molmed

MolMed is a biotechnology company focused on research, development and manufacturing of innovative therapies to treat cancer and rare genetic diseases. Starting from experience in research and development of novel anticancer and rare diseases gene therapies, MolMed invested in the development of an analytical panel, lentiviral platform based, in order to release and characterize vectors and LV genetically modified cell products. All the assays have been studied and optimized in order to achieve the best optimization in term of volume of sample used, time for the analysis, applicability of different projects and GMP suitability according ICH Q2 (R1) guidelines.

Each test is developed in order to be suitable for clinical trial application and to be complete validated in case of marketing submission. Increase robustness, accuracy and throughput by automation decreasing method variability are goals, which are in continuous improvement.

Francesca Rossetti, Analytical Methods Development Manager, MolMed

Giuliana Vallanti, Development and Quality Control Director, MolMed

PAST WEBINARS

 

Cord Blood and Tissue Therapies for Acquired and Genetic Brain Diseases

21 May 

Topics on the agenda included:

  • Diseases treatable with cord derived therapies
  • Outcomes in children with ASD to date
  • Preliminary studies with cord tissue MSC

Dr Joanne Kurtzberg, Professor Of Pediatrics And Pathology; Director, Marcus Center For Cellular Cures, Duke University Medical Center

WATCH ON DEMAND

 

Joanne Kutzberg, Duke University Medical School

Cracking the OA nut with selected MSCs

30 April

Sven Kili, Chief Operating Officer, Xintela discussed new approaches to osteoarthritis treatment.

Topics on the agenda included:

  • The talk will describe a new MSC based approach to addressing OA treatment
  • Describe the development of an allogeneic targeted MSC therapy
  • Update on non-clinical and clinical activities in the development of the first DMOAD

Sven Kili, Consultant CMO, Xintela

WATCH ON DEMAND

 

Sven Kili, Chief Operating Officer,  Xintela

Advanced manufacturing technologies for fulfilling the cell and gene therapy needs in Asia

23 April

Hear from Steve Oh, Institute Professor / Scientist at Bioprocessing Technology Institute, A*Star Singapore

Topics include:

  • Allogeneic stem cell manufacturing
  • Reprogramming and differentiation of pluripotent stem cells
  • Closed automated bioreactor for immunotherapies

Steve Oh, Institute Professor / Scientist at Bioprocessing Technology Institute, A*Star Singapore

WATCH ON DEMAND

 

Steve Oh

Biologic Correlative Studies as Potential Predictors of Efficacy for Innate Lymphocyte Therapies

16 April

Together with Larry Lamb, CSO, Incysus we talked about: 

  • Survival and disease progression are the best indices of effectiveness in standard of care plus therapies, but is there more that can be done along the way?
  • Recovery of normal immune cell number, diversity, phenotype, and function is a strong predictor for patients achieving continuing remission
  • This presentation will examine models of tumor genomics, quality of cell therapy graft material pre and post-manufacturing, and the process of immune recovery and function following treatment

Larry Lamb, CSO, Incysus

WATCH ON DEMAND

 

Bobby Gaspar, CEO,  Orchard Therapeutics

Imagining Limitless Possibilities: The Future of Hematopoietic Stem Cell Gene Therapies

1 April

In conversation with Bobby Gaspar, CEO, Orchard Therapeutics. Topics on the agenda included:

  • Understanding the power and versatility of hematopoietic stem cells
  • Reviewing learnings to date about the development and use of hematopoietic stem cell gene therapies
  • Envisioning potential future applications for this platform

Bobby Gaspar, CEO, Orchard Therapeutics

WATCH ON DEMAND

 

Bobby Gaspar, CEO,  Orchard Therapeutics

Building your own closed manufacturing system

31 March

Hear about how one start-up company successfully built a closed production system. Hosted by Troels Jordansen, CEO, Glycostem Therapeutics we discussed:

  • Is it affordable?
  • What are some of the pitfalls?

Troels Jordansen, CEO, Glycostem Therapeutics

WATCH ON DEMAND

 

Troels Jordansen, CEO,  Glycostem Therapeutics

 
 

"The webinar was excellent. Technically everything worked exceptionally well, and I found the whole experience great. Bobby's presentation was really interesting. I've heard him speak before, as I work at UCL, so I wasn't surprised that I found it engaging and informative. 
I'll hopefully join another of your webinars in the future."

 

Martin Anyim, Translational Research Manager, UCL

 
--------------

"Thank you so much for the opportunity to attend Terrapin webinar, I have great admiration and consideration of your work."
 

Molmed S.p.A.

 
--------------

Just wanted to let you know the webinars have been great.
 

Miltenyi Biotec